Leading research laboratory specializing on extraction, chemical process development, advanced cannabis testing and vape-smoke analysis for the psychedelic wellness industry Delic Holding Corp Inc. (CSE: DELC) (OTCQB: DELCF) announced having submitted an application with Health Canada 56 Research to allow its researchers conduct studies and tests outside psychedelic mushrooms like LSD and MDMA.
In addition, Delic Labs also applied for a dealer’s license as it aims to commercialize its psilocybin research and associated intellectual property for medical and research purposes.
Some of the work involved includes studying the extraction of pharmaceutically relevant compounds from psychedelic mushrooms and converting the extracts to into medical products. The company will also synthesize non-occurring compounds as part of its ongoing med-chem pipeline.
“Never before has a lab been authorized to test psychedelic compounds such as MDMA and LSD with the opportunity to create new medicines for the millions suffering from debilitating conditions like depression, anxiety, PTSD and Parkinson’s disease. Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market,” said Delic’s founder and CEO, Matt Stang.
